Pertuzumab, Trastuzumab, and an Aromatase Inhibitor for HER2-Positive and Hormone Receptor-Positive Metastatic/Locally Advanced Breast Cancer: PERTAIN Final Analysis.

Grazia Arpino Juan R De la Haba-Rodríguez Jean-Marc Ferrerro Sabino De Placido C Kent Osborne Dirk Klingbiel Valentine Revelant Christine Wohlfarth Raf Poppe Mothaffar F Rimawi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

The PFS benefit of pertuzumab was maintained and OS was similar between arms at final analysis. Adding pertuzumab may enhance activity in patients who do not require first-line chemotherapy for M/LABC. No new safety concerns were reported. These data provide additional evidence of the role of first-line pertuzumab and trastuzumab in HER2-positive M/LABC.

Keyphrases

epidermal growth factor receptor
metastatic breast cancer
locally advanced
squamous cell carcinoma
tyrosine kinase
rectal cancer
neoadjuvant chemotherapy
clinical trial
electronic health record
radiation therapy
young adults
lymph node
phase ii study